Updates

Alliance Pharma

November 2019

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The latest H1 shows sales up 29% to £70.3m on a constant currency basis (+10% like-for-like). Underlying pretax profit was up 25% to £15.2m. Eps were 2.3p. Net debt was £74m with leverage reduced to 1.95 timesDespite these good numbers, the shares remain under a bit of a cloud as some investors worry that there is a sense of increased risk with Alliance’s shift of emphasis towards a smaller number of big brands on its International Growth side. Sales were up 79% to £30.9m or up 21% when the new ones, Nizoral (medicated anti-dandruff shampoo) and Xonvea (treatment of nausea and vomiting of pregnancy), were excluded. On other longstanding products, Kelo-cote’s (scar reduction) sales were +20% ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Keystone Law

GB Group - Shares soar after H1 organic growth of +18% unveiled

Alliance Pharma (December 2022)

Alliance Pharma (November 2020)

Alliance Pharma (September 2020)

Alliance Pharma (May 2019)

Alliance Pharma (February 2019)

Alliance Pharma (December 2018)

Alliance Pharma - MHRA approves Diclectin for launch (July 2018)

Alliance Pharma - Looks capable of sustaining long-term growth (May 2018)

Alliance Pharma (February 2014)

Alliance Pharma (January 2014)

Alliance Pharma (October 2013)

Alliance Pharma (July 2013)

Alliance Pharma - 50% of sales from high margin â€œdevicesâ€ (May 2013)

Alliance Pharma - Stronger than anticipated margins (February 2013)

Alliance Pharma - Toxicology product about to enter "on year" (November 2012)

Alliance Pharma (August 2012)

Alliance Pharma - Ex-Deltacortril sales grow 13% (June 2012)

Alliance Pharma (February 2012)

Alliance Pharma (October 2011)

Alliance Pharma (August 2011)

Alliance Pharma (July 2011)

Alliance Pharma (June 2011)

Alliance Pharma (April 2011)

Alliance Pharma (February 2011)

Alliance Pharma - Very strong free cashflow (October 2010)

Alliance Pharma (June 2010)

Alliance Pharma - Broker sets 42p price target (May 2010)

Alliance Pharma - Portfolio of 53 mini cash cows (March 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X